Jasper Therapeutics (JSPR) Long-Term Deferred Tax (2019 - 2023)

Jasper Therapeutics has reported Long-Term Deferred Tax for 5 years, with the latest figure at $47.0 million in Q4 2023.

• On a quarterly basis, Long-Term Deferred Tax rose 36.14% year-over-year to $47.0 million in Q4 2023; TTM through Dec 2023 was $47.0 million, a 36.14% increase from a year earlier, with the FY2023 full-year figure at $47.0 million, up 36.14% from the prior year.
• Long-Term Deferred Tax was $47.0 million for Q4 2023 at Jasper Therapeutics, up from $34.5 million in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $47.0 million in Q4 2023, with the low at $12389.0 in Q4 2019.
• Average Long-Term Deferred Tax over 5 years is $13.5 million, with a median of $4.2 million recorded in 2020.
• The sharpest annual moves came in 2020 and 2023: Long-Term Deferred Tax soared 64360.41% in 2020, then jumped 36.14% in 2023.
• Over 5 years, Long-Term Deferred Tax stood at $12389.0 in 2019, then jumped by 64360.41% to $8.0 million in 2020, then jumped by 125.46% to $18.0 million in 2021, then soared by 91.55% to $34.5 million in 2022, then jumped by 36.14% to $47.0 million in 2023.
• The last three Long-Term Deferred Tax figures came in at $47.0 million (Q4 2023), $34.5 million (Q4 2022), and $18.0 million (Q4 2021), per Business Quant data.